Insider Sale Details

Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), sold a total of 6,018 shares of common stock on July 17, 2026, generating proceeds of $316,780. The transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on March 18, 2026. Sale prices varied between a weighted average of $49.9715 and $53.8716 per share.

The sales occurred in five blocks:

  • 324 shares at a weighted average price of $49.9715, with individual trade prices ranging from $49.72 to $50.3778.
  • 369 shares at a weighted average price of $51.4823, with trade prices from $50.765 to $51.7481.
  • 2,564 shares at a weighted average price of $52.318, with trade prices from $51.77 to $52.7695.
  • 2,638 shares at a weighted average price of $53.3825, with trade prices from $52.77 to $53.7685.
  • 123 shares at a weighted average price of $53.8716, with trade prices from $53.78 to $53.9781.

Option Exercise and Current Holdings

Prior to the sales, Mr. Hohl exercised stock options to acquire 1,072 shares at an exercise price of $2.48 per share, costing $2,658 in total. Following the transactions, he beneficially owns 46,054 shares of Enliven Therapeutics common stock, some of which are restricted stock units (RSUs) subject to vesting schedules, and he retains 84,966 outstanding stock options.

Recent Financing Activity

Enliven Therapeutics recently completed a public offering that raised approximately $460 million in gross proceeds. The company sold over 10.5 million shares of common stock at $37.50 per share, including the full exercise of the underwriters’ option. This follows an earlier announcement of a $400 million offering at the same price. The company also issued pre‑funded warrants at a slightly reduced price.

Market Context and Analyst Views

At the time of reporting, Enliven’s shares were trading near their 52‑week high of $54.88, with a current price of $54.33. InvestingPro data indicate a 101% return over the past six months. The biotechnology firm is valued at $3.79 billion, remains unprofitable with earnings per share of –$1.65, and is considered overvalued relative to its fair‑value estimate. Analysts maintain bullish outlooks, with price targets ranging from $59 to $80. H.C. Wainwright raised its target to $65 and retained a Buy rating, citing improved Phase 1 ENABLE trial data, while Jones Trading lifted its target to $70, also maintaining a Buy rating based on positive CML trial updates.